• Life expectancy of \>12 weeks.

• Body mass index of 18 to 32 kg/m2.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Phase I: Have histologically (laboratory test) confirmed CD20 + non-Hodgkin's lymphoma according to the World Health Organization's 2016 classification:

‣ Low grade lymphoma: follicular lymphoma (Grades 1-3a), marginal zone lymphoma, small lymphocytic lymphoma;

⁃ Other lymphoma: DLBCL (NOS: to include germinal center B-cell-like \[GCB\] and activated B-cell-like \[ABC\]), follicular lymphoma Grade 3b, mantle cell lymphoma; primary mediastinal large B-cell lymphoma.

• Phase IIa: Histologically confirmed CD20 + non-Hodgkin's lymphoma according to the World Health Organization's 2016 classification, only low grade lymphoma: follicular lymphoma (Grades 1-3a), marginal zone lymphoma, small lymphocytic lymphoma.

• Have at least one measurable lesion that is at least 1.5 cm in its largest dimension.

• Off treatment for 30 days from last anti-CD20 infusion until planned administration of CHO-H01.

• If no original sample is available, is willing and able to provide an adequate tumor biopsy sample at Screening.

• Have adequate cardiac function: without clinically significant and/or uncontrolled heart disease.

• Must be sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or be committed to use an acceptable form of birth control for the duration of the study (male), and for the duration of the study and for 3 months following the last CHO-H01 administration (female).